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Abstract
Background: The subtype distribution of lymphoid neoplasms in Southwest China was analyzed according to
WHO classifications. This study aims to analyze subtype distribution of lymphomas in southwest China.
Methods: Lymphoid neoplasms diagnosed within 9 years in a single institution in Southwest China were analyzed
according to the WHO classification.
Results: From January 2000 to December 2008, a total number of 6,382 patients with lymphoma were established,
of which mature B-cell neoplasms accounted for 56%, mature T- and NK-cell neoplasms occupied 26%, and
precursor lymphoid neoplasms and Hodgkin lymphomas were 5% and 13%, respectively. Mixed cellularity (76%)
was the major subtype of classical Hodgkin lymphoma; and the bimodal age distribution was not observed. The
top six subtypes of non-Hodgkin lymphoma were as follows: diffuse large B-cell lymphoma, extranodal NK/T-cell
lymphoma, nasal type, extranodal marginal zone lymphoma of mucosa associated lymphoid tissue, follicular
lymphoma, precursor lymphoid neoplasms, and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Extranodal lymphomas comprised about half of all cases, and most frequently involved Waldeyer’s ring,
gastrointestinal tract, sinonasal region and skin.
Conclusions: The lymphoid neoplasms of Southwest China displayed some epidemiologic features similar to those
reported in literature from western and Asian countries, as well as other regions of China, whereas some subtypes
showed distinct features. The high frequency of mature T/NK cell neoplasms and extranodal lymphomas, especially
for extranodal NK/T-cell lymphoma, nasal type, is the most outstanding characteristic of this series.
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Background
Lymphoid neoplasms are a diverse group of malignancy
that originate from either B, T or NK cell, representing
about 4% of the new cases of cancer diagnosed in China
each year, making them the ninth most common cancer
and the tenth leading cause of cancer death [1]. Previous
epidemiologic studies have shown remarkable differ-
ences in the distribution of lymphoma subtypes between
Asian and western populations [2-4]. However, the pos-
sible reasons of geographic differences in the spectrum
of lymphoma remain unknown, mainly because the
etiology of lymphoma is largely unknown, even though
some risk factors have been documented recently,
including genetic factors, abnormality of immunity, indi-
vidual susceptibilities, lifestyles, environmental expo-
sures, as well as various kinds of infections caused by
bacteria, viruses, mycoplasma and chlamydia [5].
Major progression has been made in understanding
the pathobiology of these diseases in the last two dec-
ades, leading to the development of the internationally
adopted WHO classification system and its updated ver-
sion [5,6]. From then on, many studies on lymphoma
incidence patterns or distributions were reported all
over the world. However, research on distribution of
lymphoma in Mainland China was still limited, and the
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case number was also small. In the current study, 6,382
consecutive patients diagnosed with lymphoid neo-
plasms according to WHO classification in the last nine
years were reviewed and analyzed. The purpose was to
estimate the subtype distribution of lymphomas and
major clinical features and to compare the data of ours
with those reported in the literature.
Patients and methods
The computerized database of all patients at the Depart-
ment of Pathology, West China Hospital of Sichuan
University was searched to identify patients with a diag-
nosis of lymphoma, excluding myeloid neoplasms and
plasma cell myeloma/plasmacytoma. Cases in which the
diagnoses of lymphoma were based on bone marrow
biopsy alone and cases with inadequate materials were
also excluded from this study. From January 2000 to
December 2008, a total number of 6,382 cases diagnosed
definitely with lymphoma were included. Clinical infor-
mation including demographics (age, gender) and initial
site involvement was collected from the submission of
pathological samples and application tables for
consultants.
Hematoxylin-eosin-stained sections were examined
histopathologically. For immunohistochemical staining
of paraffin-embedded sections, antibodies selected
included CD3, CD3ε, CD4, CD5, CD8, CD10, CD15,
CD20, CD21, CD23, CD30, CD43, CD45RO, CD56,
CD79a, CD99, ALK-1 (anaplastic large cell lymphoma
kinase-1), EMA (epithelial membrane antigen), cyclin
D1, BCL-2, BCL-6, Mum1,  and l light chain, Ki-67,
Granzyme B, TIA-1 (T-cell intracytoplasmic antigen-1),
TdT, EBV. In situ hybridization for EBV-encoded small
RNA (EBER) and IgH and/or TCR gene rearrangement
detected by polymerase chain reaction were performed
when the diagnosis was not clear from the histopatholo-
gic and immunophenotypic evaluation. All cases were
diagnosed and classified in accordance with the criteria
of WHO classification of Tumors of Haematopoietic
and Lymphoid Tissue (2001). The protocol of this study
was approved by the Institutional Review Board or ethi-
cal committee of West China Hospital of Sichuan Uni-
versity. Informed consent for the collection of medical
information for in patients, out patients and consultants
was obtained at their first visit.
Results
A total number of 6,382 lymphomas were included in
this study, in which 3,160 were consultant cases (49.5%)
from all regions of southwestern China. All of the sub-
types described in WHO classifications were presented
but hairy cell leukemia, intravascular large B-cell lym-
phoma, primary effusion lymphoma, T-cell large granu-
lar lymphocytic leukemia, adult T-cell leukemia/
lymphoma (ATLL) and both B- and T-cell prolympho-
cytic leukemia.
The major clinicopathologic characteristics of this ser-
ies are shown in Table 1. Of the 6,382 lymphomas, 833
were Hodgkin lymphomas (HL) and 5,549 were non-
Hodgkin lymphomas (NHL). Classical HL (CHL)
accounted for 95.8% of HL. Three quarters were mixed
cellularity (MC-CHL), and 18% were nodular sclerosis
(NS-CHL). In all cases of 5,549 NHLs, 64.4% of them
were mature B-cell neoplasms (3,571 cases). The most
common subtype was diffuse large B-cell lymphoma
(DLBCL), followed by extranodal marginal zone B-cell
lymphoma of mucosa-associated lymphoid tissue
(MALT lymphoma), follicular lymphoma (FL), chronic
lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL), mantle cell lymphoma (MCL), and Burkitt
lymphoma. In addition, 30.2% of NHLs were mature T-
and NK-cell neoplasms (1,677 cases). The most com-
mon subtype was extranodal NK/T-cell lymphoma,
nasal type (ENKTCL), followed by peripheral T-cell lym-
phoma, not otherwise specified (PTCL, NOS), anaplastic
large cell lymphoma (ALCL), angioimmunoblastic T-cell
lymphoma (AITL), subcutaneous panniculitis-like T-cell
lymphoma (SPTCL) and primary cutaneous CD30 posi-
tive lymphoproliferative disorders (PCCD30LD).
Furthermore, 5.4% of NHLs were lymphoblastic leuke-
mia/lymphoma (LBL, 301 cases), most of which were T-
lymphoblastic.
Most subtypes of lymphomas were prone to involve
males. Striking male predominance was observed for
MCL and lymphocyte rich CHL (LR-CHL) with the M/F
ratio of 3.1 and 4.8, respectively. For male patients, the
top five common subtypes were as follows: DLBCL,
ENKTCL, MC-CHL, FL and LBL; whereas for female
patients, they were DLBCL, ENKTCL, MC-CHL, MALT
and FL.
Age and sex distribution by subtypes of lymphoma is
shown in Figure 1. The most common pediatric (age
younger than 15 yr) lymphoma was MC-CHL, followed
by LBL, ALCL, Burkitt, DLBCL. For adolescents and
young adults (age 15 yr to 24 yr), MC-CHL was still the
leading subtype, followed by ENKTCL, DLBCL, and
LBL. For adults, DLBCL was the most common subtype,
followed by ENKTCL, MC-CHL, FL, and MALT. For
the elderly (aged older than 64 yr), DLBCL comprised
approximately half of all lymphomas, followed by
ENKTCL, MALT, CLL/SLL, and AITL.
In this study, extranodal lymphoma refers to lym-
phoma arising primarily from sites other than lymph
nodes, spleen, bone marrow, or mediastinum (lymph
nodes and thymus). Comparison of subtype distribu-
tion between extranodal and nodal lymphomas is
shown in Figure 2. Approximately 53.5% of all NHL
presented in extranodal sites at diagnosis. Figure 3
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shows the anatomical sites most commonly involved by
extranodal lymphomas. Lymphomas of Waldeyer’s ring,
gastrointestinal tract, sinonasal regions and skin repre-
sented most of the extranodal lymphomas. DLBCL was
found to be the most common subtype of both extra-
nodal and nodal lymphomas, followed by ENKTCL
and FL, respectively. Concerning the distribution of
histologic subtypes, those involving in particular extra-
nodal sites, DLBCL and ENKTCL made up the major-
ity of NHL in Waldeyer’s ring; DLBCL and MALT
composed over 80% of all lymphomas in the gastroin-
testinal tract; ENKTCL primarily represented the sino-
nasal lymphomas. For skin lymphomas, except for MF,
PCCD30LPD, SPTCL and ENKTCL were relatively
common. For nodal-based lymphomas, cervical, ingu-
inal, axillary, and supraclavicular lymph nodes were
frequently involved. About 76% of nodal-based lym-
phomas were NHLs, in which the top eight subtypes
were as follows: DLBCL, FL, LBL, CLL/SLL, AITL,
PTCL, NOS, ALCL, and MCL.
Discussion
Epidemiologic studies suggest that distribution of lym-
phoma subtypes differs strikingly by geographic varia-
tions [2]. But there is limited information on this
research in Mainland China. Up to now, this report
demonstrates the largest comprehensive descriptive
study of subtype distribution of lymphomas classified by
the WHO criteria in a single institution from China.
According to the latest SEER data [7], HL made up
11% of all lymphomas. In our observation, this figure
was 13%, similar to US and most of the reports from
China but a little higher than Japan and South Korea
[8-14]. As for subtypes, MC-CHL is the most common
of HL, followed by NS-CHL in this series, whereas NS-
CHL is much more frequent than MC-CHL (70% versus
Table 1 Subtypes of lymphomas (n = 6,382)
Age (year) Sex Site
Subtype No. Median Range Male Female M:F Nodal Extranodal N/E
DLBCL 2288 55 3-93 1359 929 1.5 1027 1261 0.81
ENKTCL 949 41 1-82 668 281 2.4 32 917 0.03
MALT 350 56 16-86 183 167 1.1 20 330 0.06
FL 327 54 23-83 213 114 1.9 292 35 8.34
LBL 301 19 1-71 211 90 2.3 253 48 5.27
CLL/SLL 256 60 22-88 180 76 2.4 228 28 8.14
PTCL, NOS 221 55 12-90 148 73 2 152 69 2.2
ALCL 196 27.5 4-71 118 78 1.5 151 45 3.36
AITL 185 61 20-86 124 61 2 185 0 -
MCL 175 61 20-79 132 43 3.1 126 49 2.57
Burkitt 106 15.5 2-69 78 28 2.8 49 57 0.86
SPTCL 54 33 4-68 25 29 0.9 0 54 0
LPL 44 61 30-82 25 19 1.3 34 10 3.4
PCCD30LD 37 37 2-78 18 19 0.9 0 37 -
SMZBCL 20 61.5 15-76 10 10 1 20 0 -
HSTCL 14 25 11-46 9 5 1.8 5 9 0.56
MF/SS 14 52.5 31-80 8 6 1.3 0 14 -
ETCL 7 29 17-42 5 2 2.5 0 7 -
NMZBCL 5 64 52-80 3 2 1.5 5 0 -
MC-CHL 606 31 3-89 433 173 2.5 597 9 66.3
NS-CHL 145 29 3-76 75 70 1.1 139 6 23.2
LR-CHL 35 30 4-64 29 6 4.8 35 0 -
LD-CHL 12 53 19-82 6 6 1 12 0 -
NLPHL 35 36 8-74 25 10 2.5 34 1 34
Total 6382 50 1-93 4085 2297 1.8 3396 2986 1.1
DLBCL, diffuse large B-cell lymphoma; ENKTCL, extranodal NK/T-cell lymphoma, nasal type; MALT, extranodal marginal zone lymphoma of mucosa associated
lymphoid tissue; FL, follicular lymphoma; LBL, lymphoblastic leukemia/lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; PTCL,
NOS, peripheral T-cell lymphoma, not otherwise specified; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; MCL, mantle cell
lymphoma; Burkitt, Burkitt lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; LPL, lymphoplasmacytic lymphoma; PCCD30LD, primary cutaneous
CD30 positive lymphoproliferative disorders; SMZBCL, splenic marginal zone B-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; MF/SS, mycosis fungoides/
Sezary syndrome; ETCL, enteropathy-associated T-cell lymphoma; NMZBCL, nodal marginal zone B-cell lymphoma; MC-CHL, mixed cellularity classical Hodgkin
lymphoma; NS-CHL, nodular sclerosis classical Hodgkin lymphoma; LR-CHL, lymphocyte-rich classical Hodgkin lymphoma; LD-CHL, lymphocyte-depleted classical
Hodgkin lymphoma; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma.
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20~25%) in Western countries [5,6,15]. MC-CHL has a
strong association with EBV, and Armstrong et al [16]
have proposed a three-disease model on the basis of age
and EBV status. We have found that 73.3% of MC-CHL
had EBV, whereas only one-fifth of NS-CHL cases had
EBV and EBV was negative in the remaining subtypes.
Therefore, EBV-associated disease in childhood may
contribute to the high frequency of MC-CHL in the
Figure 1 Distribution of lymphoid neoplasms by subtype, age and sex.
Figure 2 Distribution of histological subtypes in extranodal and nodal lymphoma.
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current study. However, more evidence will be needed.
Another difference is that HL shows a gradual decline
in cases with age in this series, whereas a bimodal age
curve (a peak at 15~35 years of age and a second peak
in late life) is apparent in Europe and North America.
Furthermore, report from Japan shows that a single
peak age of HL was in the elderly [10]. Nakatsuka and
Aozasa [17] have pointed out that the bimodal age
curve might be formed by the different peak ages of the
two main subtypes, MC-CHL (later years) and NS-CHL
(young adults).
Comparison on the incidence of NHL between our
findings and others is shown in additional file 1, table 1.
Similar to other reports, DLBCL was also the leading
histological subtype, but the frequency of FL was lower
than that of western countries, a phenomenon com-
monly seen in the Chinese population [18]. In China,
DLBCL is still the most common subtype of B-cell lym-
phomas, but the second most common subtype varies a
little from region to region [11-14,18-21]. Classification
of DLBCL into prognostically distinct subtypes has pro-
gressed from gene expression profiles (GEP) in research
to immunochemistry for a panel of markers which
could be done routinely [22-26]. Based on Hans’ algo-
rithm [24], 79% of the 364 cases of DLBCL in which
CD10, BCL-6 and Mum1 had been completely per-
formed in this collection were categorized into non-
GCB subtype, agreeing very well with the result of
recent research for Chinese patients [27].
It is commonly thought that mature T/NK-cell neo-
plasms display higher rates on the Asian continent than
others [28,29]. A recent large international retrospective
study validated the geographic variations and showed
the high frequency of ALCL, ALK-positive in North
America, AITL and ETCL in Europe, ATLL in Japan
and ENKTCL in Asian countries other than Japan [4].
In fact, the geographic variations also could be found
across China; ENKTCL is the most common subtype of
PTCL in Hong Kong and this group, whereas PTCL,
NOS in all other parts [11-14,18-21,30]. Peripheral T/
NK-cell lymphomas comprised 30.2% of non-Hodgkin
lymphomas in the current study, higher than other
Asian reports using WHO classification
[8-14,18-21,30,31]. This is likely due to the strikingly
high percentage of ENKTCL in this series. Research has
suggested that environmental factors including EBV
infection as well as exposure to pesticides and chemical
solvents were strongly associated with this disease
[32,33]. Considering that Sichuan province is a main
agricultural area in China, this may be explained. How-
ever, further research on this aspect should be done. In
addition, the high proportion of consultant cases
(38.4%) may also contribute to the high percentage of
ENKTCL.
As for age-specific incidence, the subtypes of pediatric
(younger than 15-year old) lymphoma are limited,
including CHL (mainly MC type), LBL, ALCL, Burkitt
and DLBCL. This is in accordance with reports in the
literature [34,35]. However, in any age group but pedia-
tric, ENKTCL takes second place following DLBCL in
this study. In addition, the median ages of most patients
were about 10 years younger than that of Japanese and
American patients [10,15]. The present findings may be
due to an impressively increased and further increasing
life expectancy and the high ratio of the aging popula-
tion in developed countries [36].
The frequency of extranodal NHL varies in different
parts of the world. Studies from Western countries have
reported the occurrence of extranodal NHL as 24-48%
of all NHL [37-40]. However, this figure is higher in
Asia, for example, Pakistan (42%), Kuwait (45%), Japan
(46.6%), Korea (55%), Thailand (58.7%), and China
(44.9%-61.4%)[8-14,18-21,41-43]. The fluctuating fre-
quency of extranodal lymphomas may be caused by
genetic and ethnic factors, as well as the diverse defini-
tion criteria. Additionally, extranodal NHL in this series
most commonly involved Waldeyer’s ring, whereas the
GI tract is reported to be the most common site in the
literature [37-39]. The relatively high frequency of
ENKTCL which mainly involves the sinonasal region
and Waldeyer’s ring may contribute to this difference.
Considering that the patients, including consultation
cases, were referred from all regions of southwest China,
the results may represent the distribution of lymphoma
subtypes in southwest China. Diagnoses made on the
bone marrow were excluded because this research was
Figure 3 Extranodal sites involved in non-Hodgkin lymphoma.
Waldeyer’s ring includes tonsil, palate, nasopharynx, pharynx and
base of tongue; GI tract (gastrointestinal tract) includes stomach,
small intestine and colon; Nose & sinuses includes nasal cavity and
paranasal sinuses; CNS, central nervous system.
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focused on lymphomas, not leukemia. This may result in
under-representation of CLL and MALT lymphoma.
However, since these diagnoses were not just based on
bone marrow biopsy, the influence was not considerable.
In conclusion, subtype distribution of lymphomas in
the current study is demonstrated and compared with
reports all over the world and inside China. No bimodal
age distribution was observed in CHL, and the major
subtype of CHL is mixed cellularity, not nodular sclero-
sis. A high percentage of extranodal lymphomas are pre-
sented, including a relatively high frequency of
ENKTCL.
Additional material
Additional file 1: Subtype distribution of non-Hodgkin lymphoma
across the world. Subtype distribution of non-Hodgkin lymphoma
across the world.
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